NEW YORK, March 6, 2012 /PRNewswire/ --Intellect Neurosciences, Inc. (OTCBB: ILNS.PK - News), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease. (Logo: http://photos.prnewswire.com/prnh/20111214/NY22484LOGO) A Notice of Allowance is a written communication from the USPTO stating its intention to grant a U.S. patent, after payment of the Government Issue fee. Upon grant of the patent, Intellect Neurosciences will request a $2 million milestone payment from a top tier global pharmaceutical company based on its licensing agreement with the company. "The fact that Intellect overcame an exceptionally high threshold for allowance set by the USPTO illustrates the strength of our patent, the significance of the underlying invention, and rewards our relentless efforts to obtain a patent of meaningful commercial value on behalf of the company and our shareholders," said Daniel G. Chain, PhD, Intellect Neurosciences chairman & CEO and inventor of the ANTISENILIN technology. "The decision by the USPTO to grant … Continue reading →

05-03-2012 18:07 Dead Doctors Don't Lie Program 02 March 2012 Monologue Dr. Wallach starts the show discussing genetic diseases. Contending that most diseases that have been deemed "genetic" such as Lou Gehrigs disease, Alzheirmer's, Type 2 diabetes and arthritis. Asserting these are due to nutritional deficiencies either in the child or in the mother during conception. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss two news articles concerning anti-depressant drugs. A study conducted by a Harvard psychologist an Irving Kirsch who has researched the "placebo effects" for over 30 years. Using data he obtained through the Freedom of Information Act has concluded that anti-depressant drug clinical trials showed no proof of efficacy. Finding that several trials showed no efficacy and a small amount showed some efficacy. Only these trials were submitted to the FDA and were ultimately approved for the market. Irving Kirsch has concluded those showing some efficacy were due to the placebo effect. Calls * Bruce has questions regarding joint pain. * JP asks questions concerning hypertension, high cholesterol and ED (erectile dysfunction). * Ray has frequent urination and sinusitis. * Greg has two questions the first concerns his father who has neuropathies in his legs and … Continue reading →

05-03-2012 18:36 Dead Doctors Don't Lie Program 02 March 2012 Monologue Dr. Wallach starts the show discussing genetic diseases. Contending that most diseases that have been deemed "genetic" such as Lou Gehrigs disease, Alzheirmer's, Type 2 diabetes and arthritis. Asserting these are due to nutritional deficiencies either in the child or in the mother during conception. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss two news articles concerning anti-depressant drugs. A study conducted by a Harvard psychologist an Irving Kirsch who has researched the "placebo effects" for over 30 years. Using data he obtained through the Freedom of Information Act has concluded that anti-depressant drug clinical trials showed no proof of efficacy. Finding that several trials showed no efficacy and a small amount showed some efficacy. Only these trials were submitted to the FDA and were ultimately approved for the market. Irving Kirsch has concluded those showing some efficacy were due to the placebo effect. Calls * Bruce has questions regarding joint pain. * JP asks questions concerning hypertension, high cholesterol and ED (erectile dysfunction). * Ray has frequent urination and sinusitis. * Greg has two questions the first concerns his father who has neuropathies in his legs and … Continue reading →

05-03-2012 18:38 Dead Doctors Don't Lie Program 02 March 2012 Monologue Dr. Wallach starts the show discussing genetic diseases. Contending that most diseases that have been deemed "genetic" such as Lou Gehrigs disease, Alzheirmer's, Type 2 diabetes and arthritis. Asserting these are due to nutritional deficiencies either in the child or in the mother during conception. Pearls of Wisdom Doug Winfrey and Dr. Wallach discuss two news articles concerning anti-depressant drugs. A study conducted by a Harvard psychologist an Irving Kirsch who has researched the "placebo effects" for over 30 years. Using data he obtained through the Freedom of Information Act has concluded that anti-depressant drug clinical trials showed no proof of efficacy. Finding that several trials showed no efficacy and a small amount showed some efficacy. Only these trials were submitted to the FDA and were ultimately approved for the market. Irving Kirsch has concluded those showing some efficacy were due to the placebo effect. Calls * Bruce has questions regarding joint pain. * JP asks questions concerning hypertension, high cholesterol and ED (erectile dysfunction). * Ray has frequent urination and sinusitis. * Greg has two questions the first concerns his father who has neuropathies in his legs and … Continue reading →

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Foundation Medicine, Inc., a molecular information company that brings comprehensive cancer genomic analysis to routine clinical care, today announced a collaboration with Array BioPharma (NASDAQ: ARRY - News). Foundation Medicine will use its genomic sequencing and analytic capabilities to assess potentially relevant molecular alterations to assist Array in targeting patients that are most likely to respond to treatment. Foundation Medicine has established a remarkable portfolio of collaborations around the discovery and clinical development of targeted cancer therapeutics, said Michael J. Pellini, M.D., president and chief executive officer of Foundation Medicine. The molecular information generated by our platform is designed to help biopharma companies like Array expedite the development of targeted drug candidates that impact the genomic pathways driving a specific cancer. Array has a portfolio of targeted cancer agents in early stages of clinical development. Through this collaboration with Foundation Medicine, Array intends to determine the genetic profile of tumors of patients who are treated with certain of its anticancer agents. The goal of this work is to understand how to identify patients who may respond to a given targeted therapy to ensure that each patient gets the optimal drug to treat their individual disease. Foundation Medicines … Continue reading →

Eight mutations occurred in the common bacteria Staphylococcus aureus as it turned from an innocuous resident inside one persons nose into a fatal blood infection, an Oxford University study has found. The study, which sequenced the complete DNA of the bacteria at regular time intervals, was able to identify for the first time the genetic changes that accompanied the transition to a dangerous infection. Understanding the biological causes of serious bacterial infections could help guide screening in hospitals, and could inform efforts to develop vaccines against such infections. The study is published in the journal PNAS and was carried out in partnership with Oxford University Hospitals NHS Trust through the National Institute of Health Research (NIHR) Oxford Biomedical Research Centre. "We have observed a significant genetic change in the bacteria corresponding with the development of a fatal blood infection," said Dr Bernadette Young of the Nuffield Department of Clinical Medicine at Oxford University, one of the lead researchers. "It is one case study we simply dont know how much these results will be mirrored in others. But it could be a step towards identifying genetic changes that may be important in driving infection generally." S. aureus is common, with one … Continue reading →

Editor's Choice Main Category: Genetics Article Date: 06 Mar 2012 - 9:00 PST email to a friend printer friendly opinions Current Article Ratings: At the university's Genomics and Pathology Services (GPS), the researchers will sequence the patient's DNA at no cost to the advocacy groups or to patients. Jimmy Lin, Ph.D., research instructor in pathology and immunology, explained: Rare genetic diseases range from Neimann-Pick, a metabolic disorder which can occur in infancy, to Huntington's disease, a neurodegenrative disorder diagnosed in adulthood. DNA sequencing is currently faster, cheaper and more accurate, as a result of advances in technology in recent years. For individuals suffering with rare diseases, researchers are now able to use DNA sequencing in order to identify the genetic flaw or flaws most likely responsible for their disease. It is believed that several rare diseases are caused by genetic mutations in the small part of the DNA that codes for proteins, collectively known as the exome. The researchers will sequence this part of the DNA. In early 2011, the genetic causes for 39 rare diseases were identified using exome sequencing, and according to scientists, this is just the start. Karen Seibert, Ph.D., director of GPS and research professor of … Continue reading →

TUESDAY, March 6 (HealthDay News) -- New research offers potential insight into the connection between cancer, obesity and longevity in humans by showing that genetically modified mice live longer, skinnier and almost cancer-free lives. There are quite a few differences between mice and humans, especially in regard to the type of fat that's apparently affected by the genetic tweak, so there's no way to know if the research could lead to benefits in humans. Even if medications based on the research are developed, no one knows what the side effects in people might be or their eventual cost. Still, a potential drug "could have two benefits: adding some extra protection against cancer and protecting us from overeating," said Manuel Serrano, senior group leader at the Spanish National Cancer Research Center in Madrid and co-author of a study appearing in the March issue of Cell Metabolism. At issue is a gene called Pten that boosts the body's cancer-fighting powers. Mutations in the gene can contribute to the development of cancer. The researchers genetically engineered mice to have extra copies of the gene. The mice didn't suffer from side effects, Serrano said, and they managed to live 15 percent longer than other … Continue reading →

SILVER SPRING, Md.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB:NVLX), an emerging biotechnology provider of cell and gene therapy solutions, today pointed out the potential for substantial partnership and licensing opportunities using the companys cell encapsulation technology for applications in stem cell research and medicine. Migration of implanted cells away from the target site and host rejection have been recognized as fundamental challenges faced by the stem cell community regarding their use in therapy, which the companys technology overcomes. The technology being acquired from associate SG Austria is used to place live stem cells into strong, flexible and permeable capsules. These capsules can then be implanted into animals or humans for specific therapies. Stem cells can then exist at the desired location inside the capsules, prevented from migrating and protected from the immune system that aims to eliminate such foreign cells from the body. Stem cell therapy is being used by clinicians throughout the world for treating such diverse diseases as spinal cord injury, amyotrophic lateral sclerosis, burns, glioma, multiple myeloma, arthritis, heart disease, stroke, Stargardt's Macular Dystrophy, and age-related macular degeneration, among others, most of which can be found at ClinicalTrials.gov. Historically, researchers have faced numerous difficulties in succeeding with certain stem … Continue reading →